Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    11-C-0231
Show Display Options
Rank Status Study
1 Suspended Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: CT-011 (Anti-PD1 Antibody);   Other: Sipuleucel-T (Provenge);   Drug: Cyclophosphamide

Study has passed its completion date and status has not been verified in more than two years.